SOLO- PoC Oncology: Specific in vitro, ex-vivo and in vivo pharmacology studies for new approaches to cancer treatment
SOLO Oncology is our solution for the growing need for preclinical pharmacological evaluation of proof of concept for innovative therapeutic approaches and products in oncology and immuno-oncology. Within the SOLO Oncology service offering, our teams of experts apply their know-how in laboratories equipped with state-of-the-art equipment.
Since 1995, we have been supporting your evaluation of therapeutic targets and the in vitro and in vivo pharmacological effects of products at different drug discovery stages.
More than 25 years of experience in preclinical studies focusing on the characterization and qualification of the therapeutic potential of very diverse therapeutic approaches and modalities – chemical entities, peptides, oligonucleotides, biological entities, gene and cell therapies, oncolytic viruses, vaccines and others, as single agents or in combination.
SOLO Oncology is the right solution to evaluate and predict:
the in vitro and in vivo potential of your targets of interest,
the mechanisms of action
the efficacy of your innovative products in oncology and immuno-oncology.
Our innovative technologies at the service of your research and development programs
SOLO Oncology is based on the recognized quality and innovation introduced in our precision medicine technology modules:
TOT®: Qualify the potential of your molecules and targets with our tools such as phenotypic tests, organoids of human primary tumors
Predict® – Oncology: Select your best drug candidates with our in vitro 2D and 3D models, in vivo models of ectopic and orthotopic xenografts, syngenic, CDX, chemo-induced
Chi-mice®: Evaluate your new therapeutic approaches on our humanized in vivo, PDX, transgenic models
Pharmimage®: Monitor the effect of your treatments and define your biomarkers thanks to our multi-modal platform in translational pharmacoimaging in vivo